phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL

Boston - Triplet therapy with pirtobrutinib, venetoclax, and rituximab as a two-year fixed-duration therapy improves progression free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared to standard of care venetoclax plus rituximab therapy, according to interim data from the randomized, phase 3 BRUIN CLL-322 clinical trial. Matthew Davids, MD, MMSc, Chief of the Division of Lymphoma at Dana-Farber Cancer Institute, presented the results in the Late-Breaking Abstract session at the European Hematology Association 2026 Congress in Stockholm, Sweden, on June 14, 2026.

June 15, 2026


June 26 2026

June 25 2026

June 24 2026

June 23 2026

June 22 2026

June 21 2026

June 19 2026

June 18 2026

June 17 2026

June 16 2026

June 15 2026

June 14 2026

June 13 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy